Drug Target Discovery
What we offer?
We offer an innovative service for the rational selection of molecularly-driven drug targets and therapeutic agents suitable for a broad range of clinical applications.
Our service was established with an intention to improve on the initial phases of the drug development process, which hampers the effective launch of new drugs in the market. We focus on the identification of valid drug targets and therapeutic agents based on the acquired knowledge on molecular mechanisms associated with disease onset or progression and assessment of its functional relevance in appropriate model systems. As such, the service is based on the comprehensive, multi-layer, proteomics-centered assessment of clinical samples (patient-centered approach), in combination with systems biology.
Specifically, the offered service includes:
- Proteomics analysis of clinical specimens using high-resolution mass spectrometry,
- Multi-layer analysis of experimentally derived tissue proteomics data, supplemented with literature data and transcriptomics data,
- Systems Biology approaches to understand disease mechanisms,
- Data interpretation in the context of disease biology,
- Verification of the functional relevance of selected drug targets/ therapeutic agents using in vitro and in vivo experiments.
We offer a customized service to address in the best way your needs. For more information, please click on this link [What we offer? (PDF)].
Our approach to ease drug development
To ease drug development, we have developed an approach focusing on an in-depth characterization of proteins. Proteins are the key building blocks of life and regulate all biological functions. Therefore, changes in the proteome of disease-affected tissue reflect alterations underlying disease pathophysiology.
The analytical strategy is based on the integration of high-resolution tissue proteomics data with transcriptomics data and literature mined features. Considering a high phenotypic and molecular diversity of disease, obtaining extensive information on disease-associated changes is crucial when aiming at the improvement of available therapies. This creates a strong background for:
- Identification of novel therapeutic agents based on the existence of relationship between disease, proteins, and drugs,
- Identification of new drug targets through linking the molecular changes to the disease aetiology via bioinformatics analysis. This allows to reveal affected molecular pathways and as such, identify molecules that cause the disease (being best-suited targets).
The technological and practical viability of this approach is supported by various studies1,2.
The value of our approach is strengthened by multiple existing and fruitful collaborations, an established network of experts. This includes experts in clinical proteomics, MS-based technologies, bioinformatics, systems biology, transcriptomics, pre-clinical studies and medical experts. This allows for the effective development and translation of technological advancements and innovative approaches into industrial sector and clinical practice.
This approach represents innovation and uniqueness, as summarised below.
Benefits of the approach
The above approach results in:
- reduced time required for drug development,
- increase in success rates due to the employment of ideal animal model systems, and
- reduced number of patients to be included in registration trials,
All these factors will substantially reduce R&D costs and provide a higher chance for success of the launch of new drugs in a shorter period of time.
- Break-through service based on highly advanced technology and proprietary software/ tools designed specifically to satisfy your demand.
- Unique approach focused on rational selection of therapeutic agents and drug targets based on the high-quality human-derived molecular data and disease-associated mechanisms.
- Access to unique high-resolution proteomics data in the context of cardiology, oncology, and other fields. We define proteome-based molecular disease pathophysiology which allows us to identify best-suited drug targets and therapeutic agents.
- Understanding of disease biology through the thorough assessment of molecular changes underlying disease.
- Multi-dimensionality of the data allows to better address disease heterogeneity.
- Highly personalized service. We are open to adjusting the service based on your demands.
- Benefits from the use of our service are inevitable: higher chances of the launch of new drugs into the market at lower costs, and in a shorter time.
Examples of potential applications
- Identification of novel drug targets and therapeutic agents to improve the management of heart failure.
Current HF medications, although beneficial in relieving symptoms, often do not tackle the underlying pathological mechanism or cause. There is, therefore, a pressing need to develop novel therapies that will address this issue and restore the cardiac function. For more information about Heart Failure, please visit the Cardiovascular Diseases section on our website.
Proprietary high-resolution technologies are used to identify protein changes in HF using human heart biopsies and urine samples. The approach helps to define disease at the molecular level in the affected tissue. Combined with extensive literature data and cutting-edge bioinformatics tools, the modeling of the disease is achieved leading to the definition of relevant and underlying molecular pathways and ultimately the selection of the best therapeutic targets. The functional relevance of the targets is then further investigated in animal models via intervention studies guiding the development of novel drugs directly addressing molecular causes of heart failure.
For more information, please click on this link [Drug Development Heart Failure Brochure (PDF)]
1. Latosinska, A. et al. Proteomics analysis of bladder cancer invasion: Targeting EIF3D for therapeutic intervention. Oncotarget 8, 69435-69455, doi:10.18632/oncotarget.17279 (2017).
2. Latosinska, A. et al. Integrative analysis of extracellular and intracellular bladder cancer cell line proteome with transcriptome: improving coverage and validity of -omics findings. Sci Rep 6, 25619, doi:10.1038/srep25619 (2016).